Navigation Links
Groupe Athena, Inc. Releases 3rd Quarter Financials, Continues Strong Revenue And Earnings Growth
Date:4/10/2013

MUMBAI, India, April 10, 2013 /PRNewswire/ -- Groupe Athena, Inc. (OTCPink: GATA) today released their quarterly report for the three months ending March 30, 2013. Revenues for the period were $13,378,452 which represents a 29% increase over the same period in 2012. Net after tax income for the period was $1,319,920 or $.03 per share.

Cumulative revenue for the trailing twelve months (ttm) was $53,569,759 with per share earnings of $.11 per share.

Cash reserves remain strong and continue to grow and long term debt remains virtually non-existent as the Company prepares to outfit its recently purchased new testing facility. The company reports it is still committed to funding all capital expenditures entirely from internal cash accruals without any shareholder dilution or debt increases.

Company Chairman, D. Purohit stated, "At Groupe Athena we strive to create shareholder value as a component of our business model and our current price to earnings ratio and share valuation is a fraction of our industry peers which is indicative of those efforts. The Indian pharmaceutical industry continues to be a global leader and experience superior growth which is creating new pathways for Groupe Athena to follow."

As previously stated, the company plans to apply for listing on the NASDAQ Bulletin Board quotation system with the completion of the audit for this fiscal year ending June 30, 2013.

To review the complete quarterly report please go to www.otcmarkets.com/stock/GATA/quote and click on "Financials"

The Indian pharmaceutical industry is increasingly focusing on exports to the United States and GATA is well positioned to help them get their products approved by the FDA for sales in the US. All of these are potential clients and the Company believes it has an advantage over competitors due to the facilities based in India, and their ability to deliver quick feedback to clients that could result in expedited order generation. With recent additions to equipment, the company will continue to take on additional contracts and continue to anticipate further growth.

About Groupe Athena, Inc.
Groupe Athena Inc. was incorporated in June 2008 and began operations on July 1 of that year. The company is a research and testing organization and helps various pharmaceutical and medical products and devices companies in India and Southeast Asia to get regulatory approvals and facilitate exports of their products to the United States. The Company accomplishes this by assisting clients from concept through development, providing consultation on regulatory requirements, filings and processes.

The company has a research and marketing facility in India that currently employs 17 consultants and marketing personnel and is working towards aggressively expanding its presence in the Indian pharmaceutical industry. The Company's web address is www.groupeathena.com

For more information contact:
Paul Cornell
Corporate Shareholder Relations, Inc.
pcornell@totalpublicrelations.com

Safe Harbor Statement
Certain statements set forth in this press release constitute "forward-looking statements." Forward-looking statements include, without limitation, any statement that may predict, forecast, indicate, or imply future results, performance or achievements, and may contain the words "estimate", "project", "intend", "forecast", "anticipate", "plan", "planning", "expect", "believe", "will likely", "should", "could", "would", "may" or words or expressions of similar meaning. Such statements are not guarantees of future performance and are subject to risks and uncertainties that could cause the company's actual results and financial position to differ materially from those included within the forward-looking statements. Forward-looking statements involve risks and uncertainties, including those relating to the Company's ability to grow its business. Actual results may differ materially from the results predicted and reported results should not be considered as an indication of future performance. The potential risks and uncertainties include, among others, the Company's limited operating history, the limited financial resources, domestic or global economic conditions -- activities of competitors and the presence of new or additional competition and conditions of equity markets.


'/>"/>
SOURCE Groupe Athena, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. Groupe Athena, Inc. Enters Multi Year Contractual Relationship With Major Bangladesh Pharmaceutical Manufacturer
2. Groupe Athena, Inc. Reports Record First Quarter Revenues, Adoption Of IFRS Accounting Standard In Anticipation Of Applying For Listing On The NASDAQ Bulletin Board
3. Groupe Athena Inc., (OTC: GATA) Reports Audited Financials, Announces Record Revenue & Profits
4. Star Scientific, Inc. Issues Statement in Response to Two Plaintiffs Purported Class Action Law Suits and Multiple Press Releases Issued by Plaintiffs Law Firms Trolling for New Clients
5. US B12 Shots releases New Article about Vitamin B12 Injections and Benefits
6. Watchdog Organization Releases Toolkit to Help Employers Navigate Pharmacy Benefits Contracts
7. CIVCO Releases Non-Invasive Stereotactic Radiosurgery (SRS) Solution for Head and Brain Tumors
8. XCHC Releases Worldwide Growth Guidance For Its Cannabinoid Treatment Centers and Formulations Targeting Critical Human Ailments, Company Acts on Own Guidance
9. ECRI Institute Releases C-Suite Watch List of Top 10 Hospital Technology Issues for 2013
10. Medical Marijuana, Inc. Releases 2012 Annual Share Holders Report and First Ever Corporate Revenue Forecasts
11. Drugs.com Releases Q4 Sales for Top 100 U.S. Drugs
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/28/2016)... 28, 2016  While Abbott,s announced purchase of ... valve repair and stent business, healthcare research firm ... more firmly into patient monitoring.  Kalorama said that ... device areas, with double-digit growth expected the next ... Advanced Remote Patient Monitoring . Abbott Laboratories ...
(Date:4/28/2016)... Calif. , April 28, 2016  Marking ... widely accessible breast and ovarian cancer risk test, ... panel analyzing 30 genes that highly impact the ... women. Available today, the Color Test analyzes hereditary ... prostate, stomach, and uterine cancers. The Color Test ...
(Date:4/28/2016)... , April 28, 2016  The blood testing ... million dollars, according to Kalorama Information and The Freedonia ... immunoassays and nucleic acid testing.  The healthcare research firm ... progress in developing blood collection stations and in improving ... in Kalorama Information,s report, Blood Testing Market ...
Breaking Medicine Technology:
(Date:4/30/2016)... , ... April 30, 2016 , ... ... announced RANKED Health , a program to critically evaluate and rank health-focused ... of the program is to provide independent, unbiased and accurate information to help ...
(Date:4/30/2016)... ... 30, 2016 , ... Orlando-based Maximized Living has selected Dr. Nick Wilson of ... Under the care of Maximized Living doctors at the London Olympics in 2012, ... Living is sending the largest contingent of elite chiropractors to Rio to support and ...
(Date:4/29/2016)... ... April 29, 2016 , ... ... the Accreditation Council for Graduate Medical Education (ACGME) that it has received accreditation ... the first accreditation of three residency programs that Memorial is currently pursuing, including ...
(Date:4/29/2016)... ... 29, 2016 , ... Dr. Bernie Siegel, (M.D.) ... MEDICINE and MIRACLES") addresses touchy topics related to Death live on Dr. ... Dr. Bernie Siegel, author of a plethora of essential books-to-read for physicians and ...
(Date:4/29/2016)... , ... April 29, 2016 , ... Spine Team Texas, ... is proud to announce one of their physicians has been invited to be a ... (Texas ACOFP) Family Practice Review conference on April 30, 2016. , Dr. R. ...
Breaking Medicine News(10 mins):